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Introduction: Tedizolid phosphate is an oxazolidinone approved for the treatment of acute
bacterial skin and skin-structure infections (ABSSSIs) and active against methicillin-resistant
Staphylococcus aureus.
Aims: The objective of this article was to review the evidence for the efficacy and safety of
tedizolid phosphate for the treatment of ABSSSI.
Evidence review: Approval of tedizolid phosphate for the treatment of ABSSSI was based
on the results of two phase III randomized controlled trials, ESTABLISH-1 (NCT01170221)
and ESTABLISH-2 (NCT01421511), comparing 6-day once-daily tedizolid vs 10-day twice-
daily linezolid. In ESTABLISH-1, noninferiority was met with early clinical response rates
of 79.5% and 79.4% in tedizolid and linezolid groups, respectively (difference 0.1%, 95% CI
–6.1% to 6.2%, with a 10% noninferiority margin). In ESTABLISH-2, noninferiority was
met with 85% and 83% rates of early clinical response in tedizolid and linezolid groups,
respectively (difference 2.6%, 95% CI –3.0% to 8.2%). Pooled data from ESTABLISH-1 and
ESTABLISH-2 indicated a lower frequency of thrombocytopenia in tedizolid-treated than in
linezolid-treated patients.
Conclusion: Tedizolid offers the option of an intravenous to oral switch, allows once-daily
administration, and presents lower risk of myelotoxicity when a 6-day course is used for the
treatment of ABSSSI. Greater economic cost associated with this antibiotic could be offset
by its shorter treatment duration and possibility of oral administration in routine clinical
practice, although either sponsored or nonsponsored postmarketing observational experience
remains essential for ultimately confirming the effectiveness and tolerability of tedizolid
outside clinical trials.
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Scope, aims, and objectives
Acute bacterial skin and skin-structure infections (ABSSSIs) are defined as bacter-
ial infections of the skin with a lesion area of at least 75 cm2.1 Their clinical
presentation is heterogenous, ranging from mild infections to life-threatening inva-
sive diseases.1,2 ABSSSIs affect both outpatients and inpatients, and an important
increase in ambulatory visits and hospital admissions for ABSSSIs has been
observed over the last two decades.3,4 This reflects increases in incidence and
severity of ABSSSI, relying at least in part on population aging and the related
expansion of comorbid conditions, which predispose to either development or
worsening of ABSSSI.1,2
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The severity of ABSSSI also depends on the causative
agent, with methicillin-resistant Staphylococcus aureus
(MRSA) being among the most feared pathogens, not
only for its well-known association with the development
of invasive infection but also because of the production of
Panton–Valentine leucocidin by community-acquired
MRSA strains.5,6 Notably, the prevalence of MRSA
among S. aureus isolates from ABSSSI may exceed 25%
in some endemic countries.7 Consequently, anti-MRSA
agents are frequently an essential component of the ther-
apeutic approach to ABSSSI.
Tedizolid phosphate (previously known as R701,
DA7218), a prodrug of tedizolid (previously TR700,
DA7157), is a novel oxazolidinone approved for the treat-
ment of ABSSSI and active against MRSA.8,9 In this review,
we discuss its antimicrobial and pharmacological properties,
as well as the available efficacy and safety data (Table 1).
Methods
A Medline/PubMed search was conducted using various
combinations of keywords and MeSH terms: “tedizolid”,
“TR-701”, “DA-7218”, “DA-7158”, and “bacterial skin
infection”. Then, pertinent full texts, as well as abstracts
and posters presented at the most recent international con-
gresses, were evaluated and discussed, and ultimately
summarized in a narrative presentation of the topic based
on the highest-available level of evidence, divided into
sections: mechanism of action, drug formulation and dos-
ing, in vitro antimicrobial activity, pharmacokinetics and
pharmacodynamics, efficacy in clinical studies, safety in
clinical studies, potential place in therapy of tedizolid
phosphate for the treatment of ABSSSI, and conclusion.
Mechanism of action
Tedizolid exerts its bacteriostatic activity by inhibiting
bacteria protein synthesis through binding of the 23S ribo-
somal RNA of the 50S subunit.10 The chemical structure
of tedizolid is similar to linezolid. Both are synthetic
molecules containing an oxazolidinone ring (ring A) and
a lateral chain at C5, which potentiates their activity
against some Gram-positive bacteria and mycobacteria.11
The major chemical difference between the two com-
pounds lies in the fact that tedizolid has a hydroxymethyl
group in the lateral chain that is responsible for its activity
against some bacterial strains with the cfr gene.12
Moreover, tedizolid has a para-oriented ring structure
(D-ring), which increases the number of binding sites
with the peptidyl transferase center, thus enhancing its
potency with respect to linezolid.
Drug formulation and dosing
Tedizolid has a double formulation for both oral and
intravenous routes, which are nearly equivalent. Due to a
prolonged half-life of more than 10 hours, tedizolid only
needs to be administered once daily, and the recommended
adult dose of tedizolid for its approved indication is 200
mg (regardless of the route of administration) for 6 days.
No dose adjustments are required in patients with hepatic
Table 1 Core evidence clinical impact summary for tedizolid phosphate for the treatment of ABSSSI







6-day once-daily oral tedizolid noninferior to 10-day twice-daily oral linezolid for
ABSSSI; similar results observed when tedizolid and linezolid administered intravenously,







Most frequent adverse events in randomised clinical trials nausea and headache;serious
adverse events rare; pooled data from ESTABLISH-1 and ESTABLISH-2 indicated lower





potential saving over line-
zolid for the treatment of
ABSSSI has been sug-
gested in a simulated
cohort
Economic analyses warranted to optimize the use of tedizolid and maximize its advan-
tages for treatment of ABSSSI (eg, short duration of treatment, activity against some
linezolid-resistant MRSA isolates, reduced toxicity)
Abbreviations: ABSSI, acute bacterial skin and skin-structure infection; MRSA, methicillin-resistant Staphylococcus aureus.
Bassetti et al Dovepress





























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
and/or renal impairment or in those undergoing
hemodialysis.11
In vitro antimicrobial activity
Tedizolid exerts potent in vitro activity against a wide
spectrum of Gram-positive bacteria, including MRSA,
methicillin-resistant S. epidermidis, and vancomycin-resis-
tant enterococci13,14 In a recently published study by
Karlowsky et al, tedizolid displayed four fold more potent
in vitro activity against S. aureus (both methicillin-suscep-
tible and methicillin-resistant strains) than linezolid.15
Similarly, tedizolid and linezolid minimum inhibitory con-
centrations (MICs) of MRSA isolates from ABSSSIs were
0.125–0.5 mg and 0.25–4 mg/L, respectively.16 In another
study involving 150 MRSA isolates, tedizolid MICs were
two- to five fold lower than those of linezolid.17 Similar
results were observed against enterococci,18 as also testified
by another study in which the in vitro activity of tedizolid
was higher than that of linezolid against 302MRSA isolates
and 220 vancomycin-resistant enterococci.19
Reduced susceptibility to tedizolid is rare, with MICs >1
mg/L having been observed in only nine cases among a
collection of 1,231 Gram-positive isolates.20 This possibly
relies on the fact that in contrast to linezolid, tedizolid largely
retains in vitro activity against Gram-positive bacteria har-
boring the cfr gene–encoded methylase enzyme.21,22 On the
other hand, chromosomal mutations in domain Vof rRNA or
ribosomal L3 or L4 proteins have been reported to confer
resistance to both linezolid and tedizolid.11,23 An additional
resistance mechanism has been found in enterococci, owing
to the presence of an ABC transporter codified by the optrA
gene carried by plasmids, which confers resistance to pheni-
cols and oxazolidinones.24
Of note, tedizolid also displays in vitro activity against
Clostridium difficile and Bacteroides fragilis.25,26 In addi-
tion, tedizolid shows more potent in vitro activity than
linezolid against the most common species of Nocardia
and some species of nontuberculous mycobacteria, includ-
ing Mycobacterium avium complex, M. abscessus, M. for-
tuitum, M. marinum, M. chelonae, and M. kansasii.27,28
Pharmacokinetics and pharmacodynamics
Oral tedizolid phosphate is converted into its active moi-
ety, tedizolid, though apical alkaline phosphatases, which
allows intestinal absorption.29 Tedizolid exhibits excellent
bioavailability (about 92%), although lower values of
83%–86% have been reported in Chinese and Japanese
patients.11 Pharmacokinetics of tedizolid after intravenous
administration are similar to those following oral admin-
istration, and thus no dose adjustments are needed when
switching routes.30
Tedizolid shows a high volume of distribution (67–80
L following a single dose, double to triple that of line-
zolid), and its binding to plasma proteins is 70%–90%.31,32
Tedizolid has a long half-life of 12 hours, and steady-state
concentrations are achieved in 3 days.33,34 Metabolism of
tedizolid occurs mostly in the liver, and the major, largely
inactive metabolite isolated from feces and urine (82% and
18%, respectively) is tedizolid sulfate.35 Pharmacokinetic
parameters of tedizolid are summarized in Table 2.
With regard to special patient populations, no particu-
lar differences are observed in pharmacokinetic parameters
between adults and adolescent individuals (12–17 years),
while no data are available for tedizolid phosphate in
subjects younger than 12 years.36 Pharmacokinetic para-
meters of tedizolid are also similar between nonobese and
both obese (body-mass index ≥30 kg/m2) and severely
obese patients (body-mass index ≥35 kg/m2), and thus no
dosage adjustments are needed in such populations.37
Based on available murine infection–model data, tedi-
zolid activity correlates best with AUC:MIC ratios and
may be reduced in the setting of granulocytopenia.38 In a
Monte Carlo simulation based on pharmacokinetic para-
meters in humans, the probability of reaching an AUC0–24:
MIC ratio of 3 was nearly zero for MICs ≥2 mg/L and
>98% for MICs ≤0.5 μg/mL.11
Table 2 Mean (SD) tedizolid pharmacokinetic parameters
Dose 200 mg OD IV/PO
Cmax (mg/L) IV 3±0.7
Cmax (mg/L) PO 2.2±0.7
t½, hours 12
AUC (mg*h/L) IV 29.2±6.2





Need for renal adjustment No
Need for hepatic adjustment No
Abbreviations: Cmax, maximum serum concentration at steady state; OD, once
daily, PO, per os (orally); t½, half-life; AUC, area under the curve at steady state.
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Efficacy in clinical studies
The efficacy of tedizolid phosphate for the treatment of
complicated SSSIs was initially evaluated in a phase II,
double-blind, randomized trial in which the drug was
administered for 5–7 days at once-daily dosages of 200,
300, and 400 mg.39 The registered clinical cure rates on
the test of cure in the clinically evaluable population
(n=164) were 98.2%, 94.4%, and 94.4% in patients treated
with daily dosages of 200, 300, and 400 mg, respectively.
In patients with isolation of S. aureus at baseline, clinical
cure rates were 96.6% overall and 96.8% when only
patients with MRSA infection were considered.39,40 The
approval of tedizolid phosphate for the treatment of
ABSSSI by the US Food and Drug Administration in
2014 and the European Medicines Agency through the
Committee for Medicinal Products for Human Use in
2015 was based on the results of two phase III randomized
controlled trials: ESTABLISH-1 (NCT01170221) and
ESTABLISH-2 (NCT01421511).8,9
ESTABLISH-1 was a phase III, randomized, double-
blind, noninferiority trial comparing 6-day once-daily oral
tedizolid vs 10-day twice-daily oral linezolid for ABSSSI,
with early clinical response at 48–72 hours as the primary
outcome measure. In the intent-to-treat (ITT) population,
332 patients were randomized to receive tedizolid and 336
to receive linezolid. Noninferiority was met by with clin-
ical response rates of 79.5% and 79.4% in the tedizolid
and linezolid groups, respectively (difference 0.1%, 95%
CI –6.1% to 6.2%, with a 10% noninferiority margin). Of
note, response rates at 7–14 days after the end of treatment
were similar between tedizolid-treated and linezolid-trea-
ted patients with MRSA infection (85.2% vs 85.6%,
respectively).9
ESTABLISH-2 was another phase III, randomized,
double-blind, noninferiority trial comparing 6-day once-
daily tedizolid vs 10-day twice-daily linezolid for ABSSI,
again with early clinical response at 48–72 hours as the
primary outcome measure and a 10% noninferiority mar-
gin. However, in this study tedizolid and linezolid were
administered intravenously, with optional oral stepdown.
In the ITT population, 332 patients received tedizolid and
334 linezolid, with 85% and 83% rates of early clinical
response, respectively (difference 2.6%, 95% CI –3.0% to
8.2%). Rates of early clinical response in patients with
MRSA infection were 83% (44 of 53) and 44 of 56
(79%) in the tedizolid and linezolid groups, respectively
(difference 4.4%, 95% CI –10.8% to 19.5%).8
Some post hoc subgroup analyses have also been per-
formed. In intravenous drug users from ESTABLISH-1
and ESTABLISH-2 (pooled ITT population), early clinical
response rates were similar in the tedizolid and linezolid
groups: 82.5% (151 of 183) and 79.6% (164 of 206),
respectively (difference 2.9%, 95% CI –4.9% to 10.7%).
Similar rates of early clinical response were also observed
in the tedizolid (391 of 481, 81.3%) and linezolid (367 of
463, 79.3%) groups in non–intravenous drug users.41
Another post hoc analysis found similar efficacy of tedi-
zolid and linezolid in outpatients from the pooled US ITT
population of ESTABLISH-1 and ESTABLISH-2. Early
clinical response was 84.2% and 79.0% in 403 tedizolid-
treated and 410 linezolid-treated outpatients, respectively
(difference 3.4%, 95% CI –2.1% to 8.8%).42
A post hoc analysis was performed in the subgroups of
patients of Latino and non-Latino origin from the pooled
ITT population. In patients of Latino origin, rates of early
clinical response were 80.2% (146 of 182) and 81.9% (140
of 171) for tedizolid and linezolid, respectively (difference
−1.65%, 95% CI −9.88% to 6.65%). Rates of clinical
response were also similar in patients of non-Latino origin:
82.2% (396 of 482) for tedizolid and 78.5% (391 of 498)
for linezolid (difference 3.64%, 95% CI −1.37% to
8.55%).43 Finally, similar rates of early clinical response
between tedizolid-treated and linezolid-treated patients
were observed in different subgroups according to various
severity measures, as well as in the subgroups of patients
with and without lower-extremity infections.44,45
A phase III, randomized, controlled, open-label trial com-
paring tedizolid and linezolid for the treatment of ABSSSI
was also conducted in Japanese patients.46 Clinical response
as an exploratory end point was assessed at 7–4 days after the
end of treatment. In the ITT population, clinical response
rates were 77.8% (56 of 72) and 80.0% (28 of 35) in tedizo-
lid-treated and linezolid-treated patients, respectively ( dif-
ference −2.2%, 95% CI −17.4% to 15.8%).46
Safety in clinical studies
The most frequent adverse events in ESTABLISH-1 and
ESTABLISH-2 were nausea (8.5% vs 13.4% in tedizolid
and linezolid groups, respectively, in ESTABLISH-1; 8%
vs 11% in tedizolid and linezolid groups, respectively, in
ESTABLISH-2) and headache (6.3% vs 5.1% in tedizolid
and linezolid groups, respectively, in ESTABLISH-1; 6% vs
11% in tedizolid and linezolid groups, respectively, in
ESTABLISH-2).8,9 Serious adverse events were rare in
Bassetti et al Dovepress
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both studies (1.5% vs 1.2% in tedizolid and linezolid groups,
respectively, in ESTABLISH-1; 2% vs 3% in tedizolid and
linezolid groups, respectively, in ESTABLISH-2).8,9
Pooled data from ESTABLISH-1 and ESTABLISH-2
indicated a lower frequency of thrombocytopenia in tedi-
zolid-treated than in linezolid-treated patients, possibly
because of the shorter treatment.47 At the posttherapy
evaluation (7–14 days after the end of treatment) the
platelet count was <150,000 cells/mm3 in 4.2% and 7.7%
of patients treated with tedizolid and linezolid, respec-
tively (relative risk 0.55, 95% CI 0.33–0.90). Similar
results were observed when patients with a baseline plate-
let count <150,000 were excluded from the analysis (3.0%
and 4.5% in tedizolid and linezolid groups, respectively;
relative risk 0.66, 95% CI 0.34–1.29)47
Marketed oxazolidinones are weak, reversible inhibitors
of monoamine oxidase (MAO) in vitro.48 In this regard, the
available data suggest a low incidence of serotoninergic
syndrome in patients treated with tedizolid, although the
fact that patients treated with serotoninergic agents were
excluded from ESTABLISH-1 and ESTABLISH-2 does not
allow to completely exclude possible interactions.48,49 No
increase in blood pressure were observed in subjects who
concomitantly received tyramine or pseudoephedrine.48,50,51
Of note, the reduced inhibitory effect on central nervous
system (CNS) monoamine oxidase could be due to the lower
CNS penetration of tedizolid compared to linezolid, as
observed in rats.52 Whether or not this could also impair
the efficacy of tedizolid in some possible off-label indications
(eg, CNS infections) deserves further investigation. Finally,
no clinically meaningful ophthalmological or neurological
alterations were observed in phase I volunteers receiving
tedizolid at supratherapeutic doses for 21 days.53
Potential place in therapy of tedizolid
phosphate for the treatment of ABSSSI
In the presence of less expansive alternatives for the treatment
active against MRSA, important considerations should be
made to delineate the precise place in therapy for tedizolid in
the treatment of ABSSSI, ultimately aiming at maximizing its
cost-effectiveness by exploiting its usefulness for early switch
to oral therapy and early discharge (a possible algorithm is
shown in Figure 1).54–56 A first important point to be taken into
account is the possibility of shorter treatment courses in com-
parison with other alternatives, including linezolid. In a simu-
lated cohort of 100 inpatients, potential savings of €39,348
were projected by replacing linezolid with tedizolid for the
treatment of suspected ABSSSI due to MRSA over a 1-year
period.57,58 Notably, projections became cost-ineffective for
simulated tedizolid treatment courses ≥9 days.57
This last consideration introduces another important
point worth of discussion, ie, advantages over linezolid
may also be conferred by the lower toxicity observed in
randomized clinical trials. However, it should be necessarily
considered that this advantage, described for approved indi-
cations, such as ABSSSI (where a short 6-day course proved
noninferior to 10-day linezolid), cannot be automatically
extrapolated to off-label indications requiring longer tedizo-
lid treatment courses, since long-term tolerability still has to
be comprehensively assessed. Nonetheless, off-label indica-
tions certainly warrant further study, due to the undoubted
theoretical advantages of less long-term toxicity than line-
zolid in such infections as osteomyelitis and mycobacterial
diseases. In this regard, the available preliminary evidence
regarding the use of tedizolid for off-label indications is
briefly summarized in Table 3.59–68 In addition, it is also
true that there is no definite proof that a less expensive shorter
course (6 days) of linezolid would be less effective than a 6-
day course of tedizolid in patients with ABSSSI.
Nonetheless, attention should be paid to the fact that the
available high-level evidence from randomized controlled
trials refers to 6-day tedizolid and 10-day courses of linezolid
therapy, and thus no firm conclusion on efficacy and safety
can currently be drawn about different treatment durations
than those evaluated in randomized controlled trials.
Pending dedicated postmarketing data, the potential for
increased risk of oxazolidine-induced thrombocytopenia
should be taken into account when treating patients with
chronic liver or kidney failure.69 On the other hand, the
reduced risk of drug–drug interactions with linezolid
might allow the use of tedizolid concomitantly with ser-
otoninergic or adrenergic agents in selected cases where an
oxazolidinone could be considered the optimal choice (eg,
possibility of step-down therapy and early discharge).
A recent systematic review and network meta-analysis
compared the effectiveness of tedizolid and other antibacter-
ial agents for treating ABSSSI caused by MRSA.70 Eligible
studies were randomized controlled trials conducted in adults
with complicated SSSIs or ABSSSIS caused by suspected or
documented MRSA, and 15 randomized clinical trials were
ultimately selected for inclusion. In fixed-effect models,
tedizolid showed superior clinical response to vancomycin
at the end of treatment (OR 1.7, 95% CI 1–3), while no
Dovepress Bassetti et al
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appreciable differences were observed between tedizolid and
other comparators (tedizolid vs ceftaroline, OR 0.7, 95% CI
0–30.6; tedizolid vs teicoplanin, OR 2.2, 95% CI 0.6–9.0).
Consistent results were generally observed in random-effect
models. Overall, these results suggest that tedizolid is an
important alternative option for the treatment of ABSSSI
due to MRSA in adults, although with the inherent
limitations of network meta-analyses, such as quality of
included studies, limited data, and publication bias,71 and
also those relying on the different types of SSSIs and out-
come definitions in the different trials. Overall, it is likely that
precise therapeutic algorithms developed toward a persona-
lized, patient-oriented decision on the best anti-MRSA




At least one of the following
Previous history of MRSA infection or colonization 






Repeated contact with the health-care system
Intensive care unit admission
Intensive procedures





Intravenous antibiotics for more than 24 hours
Stable clinical infection or clinical improvement
Absence of fever for more than 24 hours
No tachycardia, hypotension, or other signs of systemic
infection
Low LRINEC score and no suspicion of necrotizing fasciitis
Good oral absorption




Consider a non-MRSA covering regimenConsider an anti-MRSA antibiotic regimen
Consider ES/ED with oral tedizolid Inpatient parenteral
anti-MRSA regiment























Figure 1 Potential algorithm for considering tedizolid-based early switch (ES) to oral therapy and early discharge (ED) in patients with ABSSI.
Note: Potential predictors of MRSA and factors indicating suitability for ES/ED have been extrapolated from the literature; data from references 54 and 55.
Abbreviations: ABSSSI, acute bacterial skin and skin-structure infection; LRINEC, laboratory risk indicator for necrotizing fasciitis; MRSA, methicillin resistant
Staphylococcus aureus; WBCs, white blood cells.
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in order to identify precisely those patients in whom the
advantages of tedizolid are maximized and those in whom
the advantages of other alternatives (eg, linezolid, ceftaro-
line, or options allowing one-dose intravenous administration
like dalbavancin or oritavancin) could be preferable.
Finally, it is necessary to mention that either sponsored
or unsponsored postmarketing observational experience
remains essential for pragmatically confirming effective-
ness and tolerability of tedizolid outside clinical trials,
both for in-label and off-label indications.
Conclusion
Optimization of management of ABSSSI should include early
switch and early discharge, as well as targeting drug-resistant
Gram-positive bacteria, such as MRSA. The new
oxazolidinone tedizolid offers the option of intravenous to
oral switch, once-daily administration, and presents multiple
advantages over linezolid, including lower risk of gastroin-
testinal side effects, myelotoxicity, and lower risk of drug–
drug interactions with compounds with serotonergic and adre-
nergic activity. Greater economic cost associated with this
antibiotic could be offset by its shorter treatment duration
and possibility of oral administration in routine clinical prac-
tice. Efforts to expand our clinical knowledge are critical to
help practicing physicians determine where this drug fits into
the antibiotic armamentarium.
Disclosure
MB reports grants and personal fees from Pfizer, MSD,
and Cidara and personal fees from Astellas and Gilead
Table 3 Potential use of tedizolid in off-label indications and related preliminary evidence
Off-label indication Evidence
Pneumonia ● A noninferiority phase III, randomized, double-blind, double-dummy, controlled clinical trial
(NCT02019420) comparing once-daily intravenous tedizolid (200 mg) vs twice-daily intravenous linezolid
(600 mg) for 10 days for the treatment of presumed Gram-positive hospital-acquired bacterial pneumonia
or ventilator-associated bacterial pneumonia has been recently completed, and results are awaited.
● In neutropenic immunocompetent mice inoculated intranasally with Staphylococcus aureus isolates, simula-
tion of human ELF exposure to tedizolid demonstrated greater bacterial reductions than vancomycin.62
● In a rabbit model of MRSA pneumonia, production of α-toxin and Panton–Valentine leukocidin was
significantly inhibited when rabbits were treated with tedizolid or linezolid compared with vancomycin.63
● Tedizolid and linezolid showed antimicrobial and immunomodulatory properties in a murine model of
hematogenous MRSA pulmonary infection.61
Osteomyelitis and prosthetic
joint infections
● A phase II, single-arm, open-label trial evaluating tolerability, safety, and efficacy of oral tedizolid for the
treatment of bone and joint infections is ongoing (NCT03009045).
● A pilot study investigating tolerance, compliance, and efficacy of tedizolid for ≥6 weeks as monotherapy or
in combination for orthopedic device infections caused by Gram-positive cocci is currently recruiting
patients (NCT03378427).
● A case of successful treatment of VRE prosthetic joint infection has been reported.66
● Although inactive against biofilm-embedded S. aureus infection in the setting of bone and joint infections,
tedizolid seems able to prevent biofilm formation.59
● Tedizolid alone or combined with rifampin demonstrated activity in a rat model of MRSA foreign body–
associated osteomyelitis, although emergence of rifampin resistance was observed.65
CNS infections ● A successful 6-month course of tedizolid therapy for CNS nocardiosis in a multiple myeloma patient has
been described, without additional myelotoxicity being reported.64
Diabetic foot infection ● Plasma and tissue exposure observed in in hospitalized patients with diabetic foot infections after 200 mg
once-daily tedizolid may support further study for this indication.67
Catheter-related infection ● In a murine model of subcutaneous MRSA and MSSA catheter-related biofilm infection, a better response in
terms of decreased S. aureus density and bioluminescent signals after treatment with tedizolid than with
linezolid has been observed.60
Mycobacterial diseases ● Preliminary data on long-term safety in a small sample of 24 patients have been presented in scientific
congresses.68
Abbreviations: CNS, central nervous system; ELF, epithelial lining fluid; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; VRE,
vancomycin-resistant enterococci.
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